🚨: Our latest research in @bmj_rmdopen shows minimal radiographic progression in early PsA under current treatment protocols, highlighting the importance of early diagnosis and continuous monitoring.
#PsoriaticArthritis#Rheumatology#Research
https://t.co/nmyCTlk3mK
📢Our new study is out in @JAMANetworkOpen
We examined how maternal depressive symptoms during pregnancy relate to brain network development in children aged 9–15 years
https://t.co/OoOBldKSR3
🔔Thrilled to share our recent study published in The Journal of Rheumatology, which has been selected as the Editor’s Pick of the month!
📖 Read the full article and 🎥 check our interview with Dr. Proton Rahman at the link below!
Editor's Picks Spotlight
The Effect of Early Attainment of Minimal Disease Activity on Radiographic Outcomes: A Real-World Longitudinal Cohort Study in Psoriatic Arthritis
📖 https://t.co/CJ9LfDpmE3
@antrebea@ErasmusMC
📽️ https://t.co/QRrbdADPH4
Early intensive therapy in PsA.
STAMP RCT in early PsA:
•ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC)
•MDA at 3mo: 48% vs 25%
•PASI90 at 3mo: 60% vs 22%
By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. Abstract#OP0092 @RheumNow #EULAR2025
Early PsA? Treat fast, treat hard.
The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations.
Abstract#OP0092
@RheumNow#EULAR2025
“You dream of having a good career but this is over and on top of that. It’s a great surprise and honour.”
Daron Acemoglu (@DAcemogluMIT) reacting to the news of his prize in economic sciences today. Congratulations to our new laureate!
#NobelPrize
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel to Daron Acemoglu, Simon Johnson and James A. Robinson “for studies of how institutions are formed and affect prosperity.”
#NobelPrize
🚨: Early and regular radiographic assessments are essential for predicting and managing PsA progression.
Huge thanks to all patients and collaborators in the DEPAR cohort for advancing PsA research.
🚨: Our latest research in @bmj_rmdopen shows minimal radiographic progression in early PsA under current treatment protocols, highlighting the importance of early diagnosis and continuous monitoring.
#PsoriaticArthritis#Rheumatology#Research
https://t.co/nmyCTlk3mK
🚨: Older age and initial damage predict radiographic changes in PsA, while female sex offers protection. Tailoring treatment is crucial!
🚨: Insights from the DEPAR cohort highlight the value of real-world data in understanding PsA progression and treatment impacts.
🤰💊Exciting findings from our latest study investigating the association of prenatal SSRI exposure and maternal depressive symptoms on offspring white matter development from childhood to adolescence were published in @SOBP
https://t.co/IukFtqvYWF
BREAKING NEWS
The 2023 #NobelPrize in Physiology or Medicine has been awarded to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.
🤰💊🧠 Excited to share our study published in @JAMAPsych, investigating longitudinal links between prenatal SSRI exposure and child brain development. https://t.co/uIOJeFNZSq
In a Dutch cohort of newly diagnosed DMARD naïve #PsoriaticArthritis patients…
➡️ 8% had radiographic progression in 3 years
➡️ Older age, female sex, and baseline radiographic damage were determinants of future radiographic progression
#EULAR2023
Le Prix d’interprétation féminine revient à Merve DIZDAR dans KURU OTLAR USTUNE (LES HERBES SÈCHES) réalisé par Nuri Bilge CEYLAN
-
The Award for Best Actress goes to Merve DIZDAR in KURU OTLAR USTUNE (ABOUT DRY GRASSES) by Nuri Bilge CEYLAN
#Cannes2023#Palmares#BestActress